169 related articles for article (PubMed ID: 17967058)
21. Loop 1 of APOBEC3C Regulates its Antiviral Activity against HIV-1.
Jaguva Vasudevan AA; Balakrishnan K; Gertzen CGW; Borvető F; Zhang Z; Sangwiman A; Held U; Küstermann C; Banerjee S; Schumann GG; Häussinger D; Bravo IG; Gohlke H; Münk C
J Mol Biol; 2020 Nov; 432(23):6200-6227. PubMed ID: 33068636
[TBL] [Abstract][Full Text] [Related]
22. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
Liu B; Sarkis PT; Luo K; Yu Y; Yu XF
J Virol; 2005 Aug; 79(15):9579-87. PubMed ID: 16014920
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
24. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
25. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
Zhang W; Huang M; Wang T; Tan L; Tian C; Yu X; Kong W; Yu XF
Cell Microbiol; 2008 Aug; 10(8):1662-75. PubMed ID: 18419775
[TBL] [Abstract][Full Text] [Related]
26. Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.
Zhang W; Du J; Yu K; Wang T; Yong X; Yu XF
J Virol; 2010 Dec; 84(24):12903-13. PubMed ID: 20926562
[TBL] [Abstract][Full Text] [Related]
27. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
Rose KM; Marin M; Kozak SL; Kabat D
AIDS Res Hum Retroviruses; 2005 Jul; 21(7):611-9. PubMed ID: 16060832
[TBL] [Abstract][Full Text] [Related]
28. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
29. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
30. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
31. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
Schröfelbauer B; Senger T; Manning G; Landau NR
J Virol; 2006 Jun; 80(12):5984-91. PubMed ID: 16731937
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3G inhibits elongation of HIV-1 reverse transcripts.
Bishop KN; Verma M; Kim EY; Wolinsky SM; Malim MH
PLoS Pathog; 2008 Dec; 4(12):e1000231. PubMed ID: 19057663
[TBL] [Abstract][Full Text] [Related]
33. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.
Dang Y; Wang X; Esselman WJ; Zheng YH
J Virol; 2006 Nov; 80(21):10522-33. PubMed ID: 16920826
[TBL] [Abstract][Full Text] [Related]
34. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
Mbisa JL; Barr R; Thomas JA; Vandegraaff N; Dorweiler IJ; Svarovskaia ES; Brown WL; Mansky LM; Gorelick RJ; Harris RS; Engelman A; Pathak VK
J Virol; 2007 Jul; 81(13):7099-110. PubMed ID: 17428871
[TBL] [Abstract][Full Text] [Related]
35. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction.
Lisovsky I; Schader SM; Sloan RD; Oliveira M; Coutsinos D; Bernard NF; Wainberg MA
Intervirology; 2013; 56(4):258-64. PubMed ID: 23689841
[TBL] [Abstract][Full Text] [Related]
37. [The innate antiretroviral defense of human cells, based on the DNA editing].
Pupecka M; Pacak A
Postepy Biochem; 2006; 52(3):247-52. PubMed ID: 17201059
[TBL] [Abstract][Full Text] [Related]
38. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
39. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
Zhang H; Yang B; Pomerantz RJ; Zhang C; Arunachalam SC; Gao L
Nature; 2003 Jul; 424(6944):94-8. PubMed ID: 12808465
[TBL] [Abstract][Full Text] [Related]
40. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
